# Pharmacologically Modulating the Noradrenergic Arousal System to Reduce Freezing of Gait in Parkinson's Disease: a Multi-centre and Multi-modal Approach

> **NCT07316296** · PHASE3 · RECRUITING · sponsor: **Radboud University Medical Center** · enrollment: 60 (estimated)

## Conditions studied

- Parkinson's Disease (PD)
- Freezing of Gait
- Freezing of Gait Symptoms in Parkinson Disease

## Interventions

- **DRUG:** Atomoxetine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07316296
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2027-07-01
- **Final completion:** 2027-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-02-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07316296

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07316296, "Pharmacologically Modulating the Noradrenergic Arousal System to Reduce Freezing of Gait in Parkinson's Disease: a Multi-centre and Multi-modal Approach". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07316296. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*